BofA analyst Jason Zemansky downgraded Esperion (ESPR) to Underperform from Neutral with a price target of $2.50, down from $2.90, on renewed competitive concerns after Merck (MRK) posted plans last week to study its oral PCSK9, MK-0616, against Esperion’s bempedoic acid. The firm would argue this is a signal that the pharma company intends on directly challenging its small-to-mid cap rival, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion Stockholders Approve Key Proposals at Annual Meeting
- Esperion to Participate in Upcoming June Investor Conferences
- Esperion, Daiichi announce EC approved label update for NILEMDO, NUSTENDI
- Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
- Esperion’s bempedoic acid meets primary endpoint in hypercholesterolemia